PsilodexMedication × psilocybin
Your list , 0 items
Medication class

SNRI antidepressants and psilocybin.

5 records in this group. 3 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

5Records
3With human data

Overview

Reviewed 2026-10-18

SNRIs block reuptake of serotonin and noradrenaline (norepinephrine). In an online survey, reports from people taking SSRIs or SNRIs described weaker-than-expected psilocybin effects more often than reports from people taking bupropion, which does not act directly on serotonin (47–55% vs 29%; Gukasyan 2023).

Stopping an SNRI, especially suddenly, can cause withdrawal (discontinuation) symptoms (Effexor XR prescribing information). In one case report, a person who stopped duloxetine before a second psilocybin session had moderate discontinuation symptoms (Do 2024). The psilocybin trial that continued antidepressant treatment enrolled people taking SSRIs, not SNRIs (Goodwin 2023).

Their noradrenaline action can raise blood pressure and heart rate; venlafaxine's label describes dose-related increases in blood pressure (Effexor XR prescribing information). Psilocybin has been shown to raise heart rate and blood pressure in some healthy adults (Becker 2022), so the effects may add together. In the same case report, psilocybin 25 mg taken during duloxetine plus vortioxetine was followed by headache and a blood pressure rise from 119/77 to 141/93 mm Hg at 90 minutes (Do 2024).

One systematic review describes serotonin toxicity (a reaction from too much serotonin activity) from psilocybin as unlikely, because psilocybin causes minimal serotonin release (Sarparast 2022). Unlikely is not the same as impossible: the published data are small.

Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.

Also searched as SNRI · SNRIs

01 What the evidence covers

Best evidence available per medication
1Case reports
Case reports or online surveys
2Other psychedelic
Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text
2No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • Desvenlafaxine · PristiqEvidence: Other psychedelic

    Major depressive disorder (depression) in adults

    It is expected to weaken psilocybin and may add to its blood pressure rise; serotonin syndrome is considered unlikely, though not impossible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Duloxetine · Cymbalta, Drizalma SprinkleEvidence: Case reports

    Depression (major depressive disorder); Generalized anxiety disorder

    In one case, psilocybin with duloxetine was well tolerated except mild headache; blood pressure rose. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Levomilnacipran · FetzimaEvidence: No psilocybin data

    Major depressive disorder (MDD) in adults

    It is expected to make psilocybin feel weaker, as SNRIs did in a survey; its heart rate and blood pressure rise may add to psilocybin's.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Milnacipran · SavellaEvidence: No psilocybin data

    Fibromyalgia

    In a survey, people on related drugs reported weaker psilocybin effects, so it is expected to weaken psilocybin and may add to its heart-rate rise.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Venlafaxine · Effexor XREvidence: Other psychedelic

    Depression (major depressive disorder); Generalized anxiety disorder (GAD; extended-release)

    It is expected to make psilocybin feel weaker, as SSRIs do, and higher doses may add to psilocybin's blood pressure rise.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
5Dehydration or electrolyte risk
5Lowers seizure threshold or carries seizure risk
5Psychiatric reactions
5Raises blood pressure or heart rate
5Serotonergic
5Withdrawal or rebound if stopped abruptly
2Lowers blood pressure or causes orthostasis
1Liver injury

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

No provision names these medications or this group.

Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. Every medication in this group is psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
5Chisamore N, Kaczmarek ES, Doyle Z, et al. Comparing antidepressant effects of psilocybin-assisted psychotherapy in individuals unmedicated at screening versus individuals discontinuing medications. Can J Psychiatry 2025;70(10):759–767.
5Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38(5):458–470.
5Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499.
5Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716.
5Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res 2024;180:198–203.
5Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
2Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 2025;50(6):895–903.
2Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
1Do A, Michaud V, Stephan JF, et al. Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report. Front Psychiatry 2024;15:1394962.

Related classes

Records reviewed 2026-10-14. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25